Nxera Pharma Co., Ltd.
Research Nxera Pharma Co., Ltd. (4565.T) on Bullrun: market cap JPY 114.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4565.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 114.04B
- Financial periodFY2025
- RevenueJPY 29.62B
- Revenue growth2.7%
- Net income-JPY 12.53B
- Free cash flow-JPY 3.29B
- Gross margin72.3%
Valuation Snapshot
latest market cap is JPY 114.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 29.62B | -JPY 12.53B | -JPY 3.29B | 72.3% | -138.8 | JPY 20.37B | JPY 57.38B | JPY 61.00B |
| FY2024 | JPY 28.84B | -JPY 4.84B | -JPY 9.26B | 73.6% | -53.92 | JPY 32.27B | JPY 67.90B | JPY 68.52B |
| FY2023 | JPY 12.77B | -JPY 7.19B | -JPY 6.12B | 75.7% | -87.18 | JPY 49.07B | JPY 73.97B | JPY 66.81B |
| FY2022 | JPY 15.57B | JPY 382.00M | JPY 9.65B | 94.1% | 4.63 | JPY 66.56B | JPY 29.73B | JPY 57.94B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 114.04B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Nxera Pharma Co., Ltd.
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nxera Pharma Co., Ltd.'s market cap?
Nxera Pharma Co., Ltd.'s market capitalization is JPY 114.04B.
What does Nxera Pharma Co., Ltd. do?
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia.